122 related articles for article (PubMed ID: 34062187)
1. Altered expression of EGFR and miR-34a derived from serum and tumoral tissue was associated with glioblastoma multiform.
Vojdani S; Ghaderian SMH; Zali A; Rakhshan A; Oraee Yazdani S; Poursheikhani A; Bidari Zerehpoush F; Sharifi G
Exp Mol Pathol; 2021 Aug; 121():104655. PubMed ID: 34062187
[TBL] [Abstract][Full Text] [Related]
2. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
[TBL] [Abstract][Full Text] [Related]
3. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
Guo Y; He X; Zhang M; Qu Y; Gu C; Ren M; Wang H; Ning W; Li J; Yu C; Zhang H
J Neurooncol; 2020 Apr; 147(2):327-337. PubMed ID: 32170633
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform.
Swellam M; Ezz El Arab L; Al-Posttany AS; B Said S
J Neurooncol; 2019 Sep; 144(3):545-551. PubMed ID: 31422498
[TBL] [Abstract][Full Text] [Related]
6. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Gao YT; Chen XB; Liu HL
Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNA-137 is a potential biomarker for human glioblastoma.
Li HY; Li YM; Li Y; Shi XW; Chen H
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3599-604. PubMed ID: 27649660
[TBL] [Abstract][Full Text] [Related]
9. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
10. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.
Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y
Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma.
Xu G; Li JY
Tumour Biol; 2016 Aug; 37(8):10577-86. PubMed ID: 26857280
[TBL] [Abstract][Full Text] [Related]
12. A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR.
Al-Mayhani TF; Heywood RM; Vemireddy V; Lathia JD; Piccirillo SGM; Watts C
Neuro Oncol; 2019 Jun; 21(6):719-729. PubMed ID: 30590711
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs involved in the EGFR pathway in glioblastoma.
Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
[TBL] [Abstract][Full Text] [Related]
14. The Status of
Muñoz-Hidalgo L; San-Miguel T; Megías J; Serna E; Calabuig-Fariñas S; Monleón D; Gil-Benso R; Cerdá-Nicolás M; López-Ginés C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396457
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Nestin and EGFR in Patients with Glioblastoma Multiforme in a Public Hospital in Iran.
Matini AH; Mofidi Naeini M; Haddad Kashani H; Vakili Z
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2889-2894. PubMed ID: 33112545
[TBL] [Abstract][Full Text] [Related]
16. Hsa-miR-27a-3p and epidermal growth factor receptor expression analysis in glioblastoma FFPE samples.
Salmani T; Ghaderian SMH; Hajiesmaeili M; Rezaeimirghaed O; Hoseini MS; Rakhshan A; Nasiri MJ; Ghaedi H; Akbarzadeh R
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e185-e190. PubMed ID: 33029912
[TBL] [Abstract][Full Text] [Related]
17. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
[TBL] [Abstract][Full Text] [Related]
18. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
Chen J; Yang L; Wang X
Cancer Biomark; 2017 Dec; 20(4):521-526. PubMed ID: 28946553
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme.
Li WB; Ma MW; Dong LJ; Wang F; Chen LX; Li XR
Cancer Biol Ther; 2011 Sep; 12(6):477-83. PubMed ID: 21743299
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed circ_0029426 in glioblastoma forecasts unfavorable prognosis and promotes cell progression by sponging miR-197.
Zhang G; Sun W; Zhu L; Feng Y; Wu L; Li T
J Cell Biochem; 2019 Jun; 120(6):10295-10302. PubMed ID: 30548670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
